Jnana Therapeutics to Speak at RBC Capital Markets Global Healthcare Conference 2024

BOSTON, May 08, 2024 – Jnana Therapeutics, a biotechnology firm in the clinical stage, is utilizing its advanced chemoproteomics platform to create medicines for targets that have been traditionally difficult to address. The company recently shared that Dr. Joanne Kotz, its Co-founder and Chief Executive Officer, will be giving a corporate presentation at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 p.m. ET.

Jnana Therapeutics Overview

Jnana Therapeutics is dedicated to the discovery and development of novel treatments for diseases with significant unmet medical needs, using its cutting-edge RAPID chemoproteomics platform. This platform is particularly adept at targeting highly validated, yet challenging-to-drug targets. The company's research and development efforts are aimed at creating both first-in-class and best-in-class therapies. These therapies span a diverse range of medical conditions, including rare diseases and those that are immune-mediated.

A key initiative of Jnana is its lead program, JNT-517. This program focuses on an allosteric site on the phenylalanine transporter SLC6A19. JNT-517 represents a potentially pioneering oral treatment for phenylketonuria (PKU), which is a rare genetic metabolic disorder. PKU patients have an impaired ability to metabolize the amino acid phenylalanine, which can lead to severe neurological issues if not managed properly.

Strategically situated in Boston, Jnana Therapeutics boasts a team of scientific authorities in small molecule drug discovery and development. The company is supported by a highly experienced management team and backed by renowned life science investors. These investors include Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures, and AbbVie Ventures.

Jnana's approach is grounded in leveraging its novel chemoproteomics technology to address diseases that are currently underserved by existing treatments. By focusing on these difficult-to-drug targets, Jnana aims to deliver new therapeutic options that could transform patient outcomes in areas where there is a high need for innovation.

The presentation by Dr. Kotz at the upcoming RBC Capital Markets Global Healthcare Conference will provide an opportunity for stakeholders to gain insights into Jnana's strategic direction, ongoing programs, and future initiatives. This event marks an important moment for Jnana to showcase its progress and potential within the broader healthcare investment community.

Jnana Therapeutics continues to operate at the forefront of biotechnology innovation, driven by a mission to bring effective treatments to patients with serious and unmet medical needs. Through collaboration with top-tier investors and a commitment to scientific excellence, Jnana aims to redefine therapeutic possibilities and improve health outcomes for patients globally.